Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells $2,003,384.67 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 63,539 shares of Akero Therapeutics stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $31.53, for a total value of $2,003,384.67. Following the completion of the transaction, the chief executive officer now owns 605,417 shares in the company, valued at approximately $19,088,798.01. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Andrew Cheng also recently made the following trade(s):

• On Wednesday, October 16th, Andrew Cheng sold 24,992 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.14, for a total value of $778,250.88.
• On Tuesday, September 10th, Andrew Cheng sold 1,738 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total value of $45,500.84.

Akero Therapeutics Price Performance

AKRO opened at $31.23 on Monday. The stock’s 50 day moving average price is $27.36 and its 200-day moving average price is $24.25. Akero Therapeutics, Inc. has a 52-week low of $11.25 and a 52-week high of $37.00. The stock has a market capitalization of $2.16 billion, a PE ratio of -9.76 and a beta of -0.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.09. On average, equities research analysts predict that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its holdings in shares of Akero Therapeutics by 2,366.0% during the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after acquiring an additional 1,183 shares during the period. Headlands Technologies LLC grew its stake in Akero Therapeutics by 253.5% in the first quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock worth $107,000 after purchasing an additional 3,024 shares during the period. Ameritas Investment Partners Inc. raised its holdings in Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after purchasing an additional 1,030 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Akero Therapeutics in the first quarter worth $211,000. Finally, Quattro Financial Advisors LLC boosted its holdings in shares of Akero Therapeutics by 43,378.3% during the 1st quarter. Quattro Financial Advisors LLC now owns 10,000 shares of the company’s stock valued at $253,000 after buying an additional 9,977 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a report on Tuesday, September 17th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Akero Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $43.20.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.